Drug Trial Radar · NCT00889954
Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy
Last checked: Nov 19, 2026Latest source record: Sep 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
May 2009
Primary completion
Jul 2015
Study completion Jan 21, 2018
Sponsor
- Lead sponsor
- Baylor College of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Methodist Hospital Research Institute; Center for Cell and Gene Therapy, Baylor College of Medicine
- First posted
- Apr 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients have advanced stage cancer. This study is a gene transfer research study using special immune cells. The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: antibodies and T cells. Investigators hope that both will work better together. Antibodies are proteins that protect the body from diseases caused from infectious diseases and possibly cancer. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers: they both have shown promise, but have not been strong enough to cure most patients. T lymphocytes can kill tumor cells but there are normally not enough of them or they are not able to kill all the tumor cells. We have done research in which we have grown "extra" T lymphocytes. We have added genes to those T lymphocytes to help them to recognize tumor cells. Although the results have been promising, we are still doing more research in this area. Antibodies usually circulate in blood and are secreted by other cells of the immune system in response to the presence of germs or abnormal cells in the body. The antibody used in this study is called anti-HER2 (Human Epidermal Growth Factor Receptor 2). This antibody sticks to HER2-positive cancer cells because of a substance on the outside of these cells called HER2.
Conditions
- HER2 Positive Malignancies
Interventions
TGFBeta resistant HER2/EBV-CTLsBiological
Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT). Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients with dose limiting toxicity.Time frame: 6 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Houston Methodist Hospital
Houston, Texas
Texas Children's Hospital
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.